Japan Picks 24 Medical Studies For New Rule-Relaxation Program
This article was originally published in PharmAsia News
Japanese authorities have decided to relax some of the nation's regulations for 24 medical research projects on stem cells and medical equipment. The easing also is to be extended for the drug approval process and some regulations in associated fields. The 24 projects identified are among five types, including induced pluripotent stem cells and innovative equipment, regenerative medicine and cancer vaccines. One of the iPS studies on the list is a joint effort by Astellas Pharma, Takeda Pharmaceutical and the University of Kyoto. Previously, the government's rule-relaxation efforts were applied by geographical zones instead of specific projects. (Click here for more - a subscription may be required
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.